Home Cart 0 Sign in  

[ CAS No. 141699-58-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 141699-58-3
Chemical Structure| 141699-58-3
Structure of 141699-58-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 141699-58-3 ]

Related Doc. of [ 141699-58-3 ]

Alternatived Products of [ 141699-58-3 ]

Product Details of [ 141699-58-3 ]

CAS No. :141699-58-3 MDL No. :MFCD05664832
Formula : C9H17NO5S Boiling Point : -
Linear Structure Formula :- InChI Key :XXBDTKYKFFIAEY-UHFFFAOYSA-N
M.W : 251.30 Pubchem ID :10753243
Synonyms :

Calculated chemistry of [ 141699-58-3 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.89
Num. rotatable bonds : 5
Num. H-bond acceptors : 5.0
Num. H-bond donors : 0.0
Molar Refractivity : 61.83
TPSA : 81.29 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.57 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.56
Log Po/w (XLOGP3) : 0.37
Log Po/w (WLOGP) : 1.28
Log Po/w (MLOGP) : 0.34
Log Po/w (SILICOS-IT) : -0.53
Consensus Log Po/w : 0.8

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.3
Solubility : 12.6 mg/ml ; 0.05 mol/l
Class : Very soluble
Log S (Ali) : -1.64
Solubility : 5.73 mg/ml ; 0.0228 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -0.77
Solubility : 42.3 mg/ml ; 0.168 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.82

Safety of [ 141699-58-3 ]

Signal Word:Warning Class:
Precautionary Statements:P280-P305+P351+P338 UN#:
Hazard Statements:H317-H319 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 141699-58-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 141699-58-3 ]
  • Downstream synthetic route of [ 141699-58-3 ]

[ 141699-58-3 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 141699-58-3 ]
  • [ 147621-21-4 ]
Reference: [1] Synlett, 1998, # 4, p. 379 - 380
  • 2
  • [ 141699-58-3 ]
  • [ 254454-54-1 ]
YieldReaction ConditionsOperation in experiment
84% With potassium iodide In N,N-dimethyl-formamide at 110℃; for 16 h; Potassium iodide (12.9 g, 77.7 mmol) and C6 (6.5 g, 26.0 mmol) were combined in DMF (40 mL).
The reaction mixture was stirred at 110° C. for 16 h, then concentrated in vacuo, diluted with water, and extracted with EtOAc.
The combined organic layers were washed with water, then washed with saturated aqueous sodium chloride solution and dried over magnesium sulfate.
Filtration and removal of solvent in vacuo gave a residue, which was purified by silica gel chromatography (Eluant: 4:1 heptane:EtOAc) to afford C7 as a solid. Yield: 6.2 g, 21.9 mmol, 84percent. LCMS m/z 284.0 (M+1).
1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 4.28 (m, 2H), 4.46 (m, 1H), 4.64 (m, 2H).
13C NMR (100 MHz, CDCl3) δ 2.57, 28.27, 61.49, 80.09, 155.52.
83% With potassium iodide In N,N-dimethyl-formamide at 110℃; for 16 h; Tert-butyl 3-((methylsulfonyl)oxy)azetidin-1-carboxylate (2.67 g, 10.62 mmol) was dissolved in 20mL N,N-dimethyl formamide, and potassium iodide (5.3 g, 31.93 mmol) was added.
The resultant mixture was heated to 110°C and reacted for 16 h.
After the reaction, the solvent was removed by rotary evaporation, and 50mL water was added.
After extraction with ethyl acetate (3*30mL), the organic phases were combined, dried with anhydrous sodium sulphate, and filtrated.
The solvent was removed by rotary evaporation, and the residue was subjected to silica gel column chromatography (petroleum ether: ethyl acetate=4:1) to obtain the product (2.5g, yield: 83percent).
72% With potassium iodide In N,N-dimethyl-formamide at 110℃; for 7 h; Preparation 58 tert-Butyl 3-iodoazetidine-i-carboxylate; tert-Butyl 3-(methylsulfonyloxy)azetidine-1-carboxylate (Preparation 57, 8Og, 0.318 mol) and potassium iodide (159g, 0.96 mol) were mixed in dimethylformamide (500 ml_). The reaction mixture was stirred at 11O0C for 7 hours. The solvent was evaporated and the resulting residue was suspended in water (1 L). The product was extracted with ethyl acetate (80OmL). The combined extracts were washed with water, dried using anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with ethyl acetate: hexane (1 :4) to afford the title compound (64.6 g, 72percent). 1H NMR (400 MHz, DMSOd6): δ = 1.38 (s, 9H), 4.05-4.09 (m, 2H), 4.61-4.64 (m, 3H) ppm.
68% With potassium iodide In dimethyl sulfoxide at 140℃; for 2 h; Inert atmosphere Production Example 26-3
tert-Butyl 3-iodoazetidine-1-carboxylate
Potassium iodide (51.0 g, 307 mind) was added to a solution of tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate described in Production Example 26-2 (7.72 g, 30.7 mmol) in dimethylsulfoxide (80 mL) under nitrogen atmosphere at room temperature, and the mixture was stirred at 140° C. for 2 hours.
The reaction liquid was diluted with diethyl ether and water.
The aqueous layer was extracted with diethyl ether.
The combined organic layer was washed serially with an aqueous sodium pyrosulfite solution and a saturated saline solution and then dried over anhydrous sodium sulfate.
The drying agent was separated by filtration and then the resultant was concentrated under vacuum.
The residue was purified with silica gel column chromatography (n-heptane:ethyl acetate 9:1-1:1) to obtain the title compound (5.91 g, 68percent).
1H-NMR Spectrum (CDCl3) δ (ppm): 1.44 (9H, s), 4.25-4.33 (2H, m), 4.42-4.51 (1H, m), 4.61-4.69 (2H, m).

Reference: [1] Patent: US2010/190771, 2010, A1, . Location in patent: Page/Page column 11-12
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 21, p. 9055 - 9068
[3] Patent: EP3202765, 2017, A1, . Location in patent: Paragraph 0218; 0219
[4] Synlett, 1998, # 4, p. 379 - 380
[5] Patent: WO2010/131145, 2010, A1, . Location in patent: Page/Page column 77
[6] Patent: US2014/235614, 2014, A1, . Location in patent: Paragraph 0573; 0574; 0575
[7] Patent: US2003/83228, 2003, A1,
[8] Patent: US2003/105114, 2003, A1,
[9] Patent: US2001/44434, 2001, A1,
[10] Patent: US2003/162782, 2003, A1,
[11] Patent: US2002/173502, 2002, A1,
[12] Patent: US2002/22732, 2002, A1,
[13] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 5, p. 1517 - 1521
[14] Patent: EP1176147, 2002, A1, . Location in patent: Page 25
  • 3
  • [ 141699-58-3 ]
  • [ 254454-54-1 ]
YieldReaction ConditionsOperation in experiment
60% With potassium iodide In dimethyl sulfoxide; pentane Preparation 32
1- tert -Butyloxycarbonyl-3-iodoazetidine
A mixture of 1-tert-butyloxycarbonyl-3-(methylsulfonyloxy)azetidine (Preparation 31) (28g, 111mmol) and potassium iodide (170g, 1.02mol) in dimethylsulphoxide (250ml) was heated to 140°C and stirred for 2 hours.
The reaction mixture was cooled, poured into water (1000ml) and extracted with diethyl ether (x2).
The combined organic layers were washed with an aqueous solution of sodium metabisulfite, brine, dried over Na2SO4, filtered and solvent removed under reduced pressure.
The residue was purified by column chromatography on silica gel, eluding with a solvent system of ethyl acetate: pentane (1:1, by volume) to give the title compound as a pale yellow oil (19g, 60percent).
1H-NMR (CDCl3): δ = 4.65 (2H, m), 4.50 (1H, m), 4.30 (2H, m), 1.45 (9H, s).
Reference: [1] Patent: EP992493, 2000, A1,
  • 4
  • [ 124-63-0 ]
  • [ 141699-55-0 ]
  • [ 141699-58-3 ]
YieldReaction ConditionsOperation in experiment
100% With triethylamine In tetrahydrofuran at 20℃; for 2 h; Inert atmosphere Production Example 26-2
tert-Butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate
Methanesulfonyl chloride (2.57 mL, 33.3 mmol) and triethylamine (11.6 mL, 83.1 mmol) were added to a solution of commercially available N-BOC-3-hydroxy azetidine (4.8 g, 27.7 mmol) in tetrahydrofuran (100 mL) under nitrogen atmosphere at room temperature.
The reaction liquid was stirred at room temperature for 2 hours.
A saturated aqueous sodium bicarbonate solution was added to the reaction liquid at room temperature, and the mixture was diluted with ethyl acetate.
The organic layer was washed with a saturated saline solution and then dried over anhydrous sodium sulfate.
The drying agent was separated by filtration and then the filtrate was concentrated under vacuum.
The residue was purified with silica gel column chromatography (n-heptane:ethyl acetate=9:1-1:1) to quantitatively obtain the title compound.
1H-NMR Spectrum (CDCl3) δ (ppm): 1.45 (9H, s), 3.07 (3H, s), 4.03-4.18 (2H, m), 4.22-4.36 (2H, m), 5.12-5.27 (1H, m).
100% With triethylamine In dichloromethane (1)
1-t-Butoxycarbonyl-3-(methanesulfonyloxy)azetidine
To a solution of 1-t-butoxycarbonyl-3-hydroxyazetidine (3.24 g, 18.7 mmol) (obtained as described in Reference Example 31(1)) in methylene chloride (160 ml) were added methanesulfonyl chloride (1.59 ml, 20.6 mmol) and triethylamine (2.89 ml, 20.6 mmol) in an ice bath.
After stirring the mixture in the ice bath for 10 minutes, the mixture was stirred at room temperature for 6 hours.
After checking the completion of the reaction, the reaction mixture was partitioned between ethyl acetate and saturated aqueous sodium hydrogencarbonate solution.
The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
The residue was purified by chromatography on a silica gel column using n-hexane: ethyl acetate (1: 1 --> 1: 2) as the eluant to afford 1-t-butoxycarbonyl-3-(methanesulfonyloxy)azetidine (4.71 mg, yield 100percent) as a pale yellow oil.
1H-NMR (400 MHz, CDCl3): δ (ppm) 5.23 - 5.17 (1H, m), 4.28 (2H, dd, J=6.6,1.5Hz), 4.10 (2H, m), 3.07 (3H, s), 1.46 (9H, s).
99% With triethylamine In dichloromethane at 0 - 20℃; for 6 h; Methanesulfonyl chloride (21.4 g, 187 mmol) was added to a solution of tert-butyl3-hydroxyazetidine-1-carboxylate (25 g, 144 mmol) and triethylamine (21.8 g, 216 mmol) inDCM (500 mL) at 0 °C. After stirring at room temperature for 6 h, the reaction mixture waswashed with 1 M HC1 (50 mL) and the aqueous layer was extracted with DCM (100 mL x 2).The combined organic layers were dried over Na2SO4 and concentrated to give tert-butyl 3-((methyl sulfonyl)oxy)azetidine- 1 -carboxylate (36 g, 99percent) as a colourless oil. 1H NMR (400 MFIz, CDC13) (ppm): 5.21-5.16 (m, 1H), 4.28-4.24 (m, 2H), 4.10-4.07 (m, 2H), 3.05 (s, 3H), 1.43 (s, 9H).
98% With triethylamine In tetrahydrofuran at 0 - 20℃; A mixture of tert-butyl 3-hydroxyazetidine-1-carboxylate (4.98 g, 28.7 mmol) and triethylamine (4.82 mL, 62.3 mmol) in tetrahydrofuran (75 mL) was cooled to 0° C. using an ice bath. Methanesulfonyl chloride (2.46 mL, 31.8 mmol) in tetrahydrofuran (12.5 mL) was added slowly to the reaction. Once the addition was complete, the ice bath was removed and the reaction was stirred at room temperature for 4 hours. Water (100 mL) was added to the reaction, and the mixture extracted with ethyl acetate (2.x.150 mL). The combined organic phase was washed with brine (2.x.100 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford the title compound as a pale yellow oil (7.11 g, 98percent).1HNMR (CDCl3): δ 1.45 (s, 9H), 3.07 (s, 3H), 4.08-4.12 (m, 2H), 4.26-4.30 (m, 2H), 5.18-5.23 (m, 1H).LCMS Rt=2.53 minutes MS m/z 151.98 [M-Boc+H]+.
96% With triethylamine In dichloromethane at 20℃; To a solution of compound 108A (2.0 g, 11.55 mmol) in dichloromethane (10 mL) was added MsCl (1.455 g, 12.70 mmol) followed by TEA (1.519 g, 15.01 mmol). The mixture was stirred at rt overnight. The reaction was quenched with water and extracted with additional dichloromethane. The organic layer was washed, dried and concentrated to dryness to afford compound 108B (2.8 g, 96percent) as a white solid. 1H NMR (400 MHz, CDC13): δ 5.22-5.18 (m, 1H), 4.30-4.25 (m, 2H), 4.12-4.08 (m, 2H), 3.06 (s, 3H), 1.45 (s, 9H).
96% With triethylamine In dichloromethane at 0 - 20℃; To a stirred, cooled (0 °C) solution of terf-butyl 3-hydroxyazetidine-1 -carboxylate (500 mg, 2.89 mmol in DCM (5 mL) was added triethylamine (0.90 ml_, 6.46 mmol) followed by methanesulfonyl chloride (0.25 mL, 3.21 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The mixture was poured into saturated brine and extracted twice with EtOAc. The combined organic layers were dried over Na2SC>4 and filtered. Solvent was removed under reduced pressure. The remaining material was purified on silica gel eluting with a 0percent-50percent EtOAc-hexanes gradient. The appropriate fractions (identified by TLC, silica gel, 50percent EtOAc/hexanes, ΚΜηθ4 stain) were combined, evaporated under reduced pressure and placed in vacuo to give the title compound (699 mg, 96percent) as a colorless oil that slowly solidified. 1H NMR (400 MHz, CD3SOCD3) δ 1 .39 (s, 9 H), 3.25 (s, 3 H), 3.88-3.94 (m, 2 H), 4.19-4.36 (m, 2 H), 5.22-5.28 (m, 1 H); LC-MS (LC-ES) M+H-terf-Bu = 196.
94% With triethylamine In dichloromethane at 0℃; for 1 h; Example 20: 3-(2'-Trifluoromethyl-biphenyl-3-yloxy)-azetidine; Step A: Preparation of 3-Methanesulfonyloxy-azetidine-1 -carboxylic acid tert-butyl ester. To 3-hydroxy-azetidine-1 -carboxylic acid tert-butyl ester (1.21 g, 6.99 mmol) and Et3N (0.85 g, 1.2 ml_, 8.4 mmol) in CH2CI2 (35 ml_) at 0 0C was added methanesulfonyl chloride (0.88 g, 0.60 ml_, 7.7 mmol). After 1 h, brine was added and the reaction extracted with CH2CI2 (2X). The combined organics were dried to give 1.65 g (94percent) of 3-methanesulfonyloxy-azetidine-1 - carboxylic acid tert-butyl ester a yellow solid that was used without further purification. 1H NMR (CDCI3): 5.20 (tt, J = 6.7, 4.2 Hz, 1 H), 4.28 (ddd, J = 10.3, 6.7, 1.2 Hz, 2H), 4.10 (ddd, J = 10.4, 4.2, 1.1 Hz, 2H), 3.07 (s, 3H), 1.44 (s, 9H).
94% With triethylamine In dichloromethane at 20℃; for 2 h; To a mixture of tert-butyl 3-hydroxyazetidine-1-carboxylate (1, 3.15 g. 18.3 mmol) and triethylamine (12.7 ml, 91.5 mmol) in CH2Cl2 (100 mL) was added dropwise methanesulfonyl chloride (4.17 g, 36.6 mmol) at room temperature. The reaction stirred for 2 h. The mixture was diluted with EtOAc (300 mL), washed with water (100 mL) and brine (100 mL), dried (Na2SO4), filtered and concentrated to afford the title compound (4.3 g, 94percent) as a light brown oil: 1H NMR (500 MHz, CDCl3) δ 5.16-5.23 (m, 1H), 4.25-4.30 (m, 2H), 4.07-4.12 (m, 2H), 3.06 (s, 3H), 1.44 (s, 9H)
93% With triethylamine In dichloromethane at 0 - 20℃; for 20 h; A solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (97percent, 5.0 g, 28 mmol) in dichloromethane (50 mL) was treated with triethylamine (7.8 mL, 56 mmol) and cooled to 0° C. A solution of methanesulfonyl chloride (2.28 mL, 29.3 mmol) in dichloromethane was added drop-wise to the cold reaction, which was maintained at 0° C. for 2 h, then allowed to warm to room temp over the next 18 h.
Solvents were removed in vacuo and the residue was taken up in ether and filtered:
The filtrate was concentrated in vacuo, and the residue purified via silica gel chromatography (Eluant: 5:1 heptane:EtOAc, then 2:1 heptane:EtOAc) to provide C6 as a solid. Yield: 6.5 g, 26.0 mmol, 93percent. LCMS m/z 503.1 (2M+1).
1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H), 3.06 (s, 3H), 4.09 (ddd, J=10.4, 4.2, 1.2, 2H), 4.27 (ddd, J=10.4, 6.6, 1.2 Hz, 2H), 5.19 (tt, J=6.6, 4.2 Hz, 1H).
13C NMR (100 MHz, CDCl3) δ28.23, 38.33, 56.45 (br), 67.25, 80.29, 155.80.
92% With triethylamine In tetrahydrofuran at 20℃; for 4 h; Cooling with ice Tert-butyl 3-hydroxyazetidin-1-carboxylate (2.0 g, 11.5 mmol) was dissolved in 50mL tetrahydrofuran, and triethylamine (2.34 g, 23.1 mmol) was added.
Under the condition of ice water bath, methanesulfonyl chloride (1.58 g, 13.8 mmol) was added slowly.
The resultant mixture was warmed to room temperature, and further reacted for 4 h.
After the reaction, the solvent was removed by rotary evaporation, and to the residue,50mL waterwas added.
After extraction with ethyl acetate (3*50mL), the organic phases were combined, dried with anhydrous sodium sulphate, and filtrated.
The solvent was removed by rotary evaporation to obtain the product (2.67 g, yield: 92percent).
91% With diethylamine In dichloromethane at 0 - 20℃; To a solution of compound (2-3) (466 mg; 2.69 mmol) with Et3N (0.75 mL; 5.38 mmol) and 4-(dimethylamino)-pyridine (33 mg, 0.269 mmol) in 10 mL of CH2Cl2 at 0 C. was added methanesulfonyl chloride (0.25 mL 3.23 mmol). The resulting mixture of brown color solution was stirred at 0 C. to room temperature for overnight. The reaction mixture was quenched with NaHCO3, then partitioned between CH2Cl2 (200 mL) and saturated NaHCO3 solution (50 mL). The organic layer was dried (Na2SO4), then filtered through silica gel pad, eluted with hexane: EtOAc/1:1; the filtrate was concentrated by vacuum to give 614 mg (2-4) as yellow oil (91percent yield). 1H NMR (400 MHz, chloroform-D) ? ppm 1.43 (s, 9H) 3.05 (s, 3H) 4.08 (dd, J=10.36, 4.29 Hz, 2H) 4.26 (dd, J=10.36, 6.82 Hz, 2H) 5.11-5.26 (m, 1H).
91% With dmap; triethylamine In dichloromethane at 0 - 20℃; To a solution of compound (2-3) (466 mg; 2.69 mmol) with Et3N (0.75 mL; 5.38 mmol) and 4-(dimethylamino)-pyridine (33 mg, 0.269 mmol) in 10 mL of CH2CI2 at 0°C was added methanesulfonyl chloride (0.25 mL 3.23 mmol). The resulting mixture of brown color solution was stirred at 0°C to room temperature for overnight. The reaction mixture was quenched with NaHCO3, then partitioned between CH2CI2 (200 mL) and saturated NaHCO3 solution (50 mL). The organic layer was dried (Na2SO4), then filtered through silica gel pad, eluted with hexane: EtOAc/1:1; the filtrate was concentrated by vacuum to give 614mg (2-4) as yellow oil (91percentyield). 1H NMR (400 MHz, chloroform-D) 6 ppm 1.43 (s, 9 H) 3.05 (s, 3 H) 4.08 (dd, ^10.36, 4.29 Hz, 2 H) 4.26 (dd, J=10.36, 6.82 Hz, 2 H) 5.11 - 5.26 (m, 1 H).
83% With triethylamine In dichloromethane at 20℃; for 1 h; Alcohol 61 (928 mg, 5.3 mmol), Et3N (Ig, 10.7 mmol), in CH2Cl2 (20 mL), was added MsCl (733 mg, 6.4 mmol), were allowed to stirr for 1 hours at room temperature. Then the reaction mixture was diluted with diluted with CH2Cl2 (20 mL) <n="45"/>and the organic layer washed with brine (20 mL). The combined organic layer was dried over anhydrous Na2SO4 and evaporated. Purification of the resulting crude by flash silica gel chromatography provided the mesolate compound (1.11 g, 83percent) as an oil.
78% With triethylamine In dichloromethane at 20℃; Cooling with ice Preparation 57 tert-Butyl 3-(methylsulfonyloxy)azetidine-1-carboxylate; tert-Butyl 3-hydroxyazetidine-i-carboxylate (71g, 0.41 mol) was dissolved in dichloromethane (70OmL). Triethylamine (114mL, 0.82 mol) was added and the solution was cooled in an ice bath before the addition of methanesulfonyl chloride (33.4mL, 0.43 mol) as a solution in dichloromethane (10OmL). The reaction mixture was stirred at room temperature overnight and evaporated. The residue was dissolved in ether (50OmL), triethylamine hydrochloride was filtered off, and the filtrate was evaporated. The residue was purified by column chromatography on silica gel eluting with hexane:ethyl acetate (3:1 ) to afford the title compound (80 g, 78percent). 1H NMR (400 MHz, DMSOd6): δ = 1.38 (s, 9H), 3.23 (s, 3H), 3.90-3.94 (m, 2H), 4.19-4.24 (m, 2H), 5.22-5.28 (m, 1 H) ppm.
70% With triethylamine In dichloromethane at 0 - 20℃; for 1 h; To a stirred solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (1.2 g, 6.92 mmol) inDCM (20 mL) was added TEA (2.0 mL, 13.8 mmol) followed by methane sulfonylchloride (0.80 mL, 10.3 mmol, spectrochem) at 0 00. The reaction mixture was stirred atRT for 1 h. Reaction completion was monitored by TLC. Reaction mixture was dilutedwith water and extracted in dichloromethane (2x50 mL). The combined extract waswashed with water, brine solution and dried over anhydrous Na2SO4 and concentrated. The crude product was isolated as pale yellow gum and was used as such for next step without further purification (1.2 g, 70percent). 1H NMR (400 MHz, DMSO-d6): 6 5.26-5.23 (m, 1 H), 4.23 (t, J = 9.6 Hz, 2H), 3.92 (d, J = 6.8 Hz, 2H), 3.24 (s, 3H), 1.37 (s, 9H). LCMS:(Method A) 152.0 (M-Boc-fH), Rt. 3.48 mm, 99.7 percent (Max).
68% With triethylamine In dichloromethane at 0 - 20℃; To a solution of 3-Hydroxy-azetidine-1 -carboxylic acid tert-butyl ester (2.0 g, 1 1 .2 mmol) and Et3N (3.12 ml, 22.4 mmol) in DCM (20 ml) was added MsCI (0.92 ml, 1 1 .6 mmol) dropwise at 0°C . The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with brine (20 ml) and was extracted with ethyl acetate (20 mL χ 2). The combined organic layers was dried over anhydrous Na2S04, filtered and concentrated in vacuum. The crude product was purified by column chromatography on silica gel (eluted with petroleum ether/EtOAc = 10:1 to 2:1 ) to give compound A10-1 (2.0 g, 68
2.32 g With triethylamine In chloroform at 0 - 20℃; for 0.5 h; N-Boc-3-hydroxyazetidine (1.73 g) was dissolved in chloroform (20 ml). Triethylamine (2.09 ml) and methanesulfonyl chloride (856 μl) were added thereto at 0°C. After stirring at room temperature for 0.5 hours, ethyl acetate and water were added thereto to separate the organic layer. After being washed with a saturated aqueous sodium bicarbonate solution, a saturated aqueous ammonium chloride solution, and water, the organic layer was dried over anhydrous sodium sulfate. The solvent was then distilled off under reduced pressure to obtain the title compound as a colorless, oily compound (2.32 g). Physical properties: m/z[M+H]+ 252.0
2.32 g With triethylamine In chloroform at 0 - 20℃; for 0.5 h; N-Boc-3-hydroxyazetidine (1.73 g) was dissolved in chloroform (20 ml). Triethylamine (2.09 ml) and methanesulfonyl chloride (856 μl) were added thereto at 0° C. After stirring at room temperature for 0.5 hours, ethyl acetate and water were added thereto to separate the organic layer. After being washed with a saturated aqueous sodium bicarbonate solution, a saturated aqueous ammonium chloride solution, and water, the organic layer was dried over anhydrous sodium sulfate. The solvent was then distilled off under reduced pressure to obtain the title compound as a colorless, oily compound (2.32 g). Physical properties: m/z[M+H]+ 252.0
2.32 g With triethylamine In chloroform at 0 - 20℃; for 0.5 h; N-Boc-3-hydroxyazetidine (1.73 g) was dissolved in chloroform (20 ml). Triethylamine (2.09 ml) and methanesulfonyl chloride (856 μl) were added thereto at 0° C. After stirring at room temperature for 0.5 hours, ethyl acetate and water were added thereto to separate the organic layer. After being washed with a saturated aqueous sodium bicarbonate solution, a saturated aqueous ammonium chloride solution, and water, the organic layer was dried over anhydrous sodium sulfate. The solvent was then distilled off under reduced pressure to obtain the title compound as a colorless, oily compound (2.32 g). Physical properties: m/z [M+H]+ 252.0

Reference: [1] Patent: US2014/235614, 2014, A1, . Location in patent: Paragraph 0570; 0571; 0572
[2] Patent: EP1340757, 2003, A1,
[3] Journal of Medicinal Chemistry, 2014, vol. 57, # 18, p. 7731 - 7757
[4] Patent: WO2018/102419, 2018, A1, . Location in patent: Paragraph 0344; 0345; 0346; 0347
[5] Patent: US2012/10182, 2012, A1, . Location in patent: Page/Page column 40
[6] Chemistry - A European Journal, 2018, vol. 24, # 33, p. 8343 - 8349
[7] Organic Process Research and Development, 2015, vol. 19, # 12, p. 2067 - 2074
[8] Patent: WO2016/3929, 2016, A1, . Location in patent: Paragraph 0417
[9] Patent: WO2018/69863, 2018, A1, . Location in patent: Page/Page column 100
[10] Organic Letters, 2014, vol. 16, # 23, p. 6160 - 6163
[11] Journal of Medicinal Chemistry, 2018, vol. 61, # 7, p. 2753 - 2775
[12] Patent: WO2010/59390, 2010, A1, . Location in patent: Page/Page column 52
[13] Patent: US2014/140956, 2014, A1, . Location in patent: Paragraph 0690; 0691
[14] Patent: US2010/190771, 2010, A1, . Location in patent: Page/Page column 11-12
[15] Journal of Medicinal Chemistry, 2012, vol. 55, # 21, p. 9055 - 9068
[16] Patent: EP3202765, 2017, A1, . Location in patent: Paragraph 0216; 0217
[17] Patent: US2006/46991, 2006, A1, . Location in patent: Page/Page column 57-58
[18] Patent: WO2006/21881, 2006, A2, . Location in patent: Page/Page column 62; 63
[19] Journal of Medicinal Chemistry, 2011, vol. 54, # 18, p. 6342 - 6363
[20] Patent: WO2008/133734, 2008, A2, . Location in patent: Page/Page column 42-43
[21] Patent: WO2010/131145, 2010, A1, . Location in patent: Page/Page column 76
[22] Patent: WO2014/198808, 2014, A1, . Location in patent: Page/Page column 144
[23] Patent: WO2013/53690, 2013, A1, . Location in patent: Page/Page column 38
[24] Journal of Medicinal Chemistry, 2001, vol. 44, # 1, p. 94 - 104
[25] Patent: US2002/156081, 2002, A1,
[26] Patent: US6921763, 2005, B2,
[27] Patent: US2008/90799, 2008, A1, . Location in patent: Page/Page column 18
[28] Patent: WO2009/62118, 2009, A2, . Location in patent: Page/Page column 218
[29] Patent: WO2009/106577, 2009, A1, . Location in patent: Page/Page column 117-118
[30] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 10, p. 2742 - 2746
[31] Patent: EP2202223, 2010, A1, . Location in patent: Page/Page column 44
[32] Patent: EP2236507, 2010, A1, . Location in patent: Page/Page column 27-28
[33] Patent: WO2011/44001, 2011, A1, . Location in patent: Page/Page column 35-36
[34] Patent: WO2011/160020, 2011, A2, . Location in patent: Page/Page column 76-77
[35] Patent: EP2657233, 2013, A1, . Location in patent: Paragraph 0205; 0206
[36] Patent: WO2014/28800, 2014, A1, . Location in patent: Page/Page column 59
[37] Journal of Medicinal Chemistry, 2014, vol. 57, # 18, p. 7499 - 7508
[38] Patent: EP2813505, 2014, A1, . Location in patent: Paragraph 0232
[39] Patent: WO2015/89809, 2015, A1, . Location in patent: Page/Page column 89
[40] Patent: WO2015/95256, 2015, A1, . Location in patent: Page/Page column 89
[41] Patent: US2015/175604, 2015, A1, . Location in patent: Paragraph 1046; 1047
[42] Patent: US2016/136168, 2016, A1, . Location in patent: Paragraph 0297
[43] Patent: US2016/193210, 2016, A1, . Location in patent: Paragraph 0299
[44] Patent: WO2017/12576, 2017, A1, . Location in patent: Page/Page column 192
[45] Patent: WO2016/206101, 2016, A1, . Location in patent: Page/Page column 88; 89
[46] Patent: US2018/271837, 2018, A1, . Location in patent: Paragraph 0156-0157
[47] Patent: WO2009/105717, 2009, A1, . Location in patent: Page/Page column 62
  • 5
  • [ 24424-99-5 ]
  • [ 36476-89-8 ]
  • [ 141699-58-3 ]
YieldReaction ConditionsOperation in experiment
38% With triethylamine In dichloromethane for 3 h; The starting materials were prepared as follows : 3-Methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester To a solution of 3-METHANESULFONATOAZETIDINIUM CHLORIDE (1. 05 g, 5. 65 mmol ; Anderson, et AL., J. Org. CHEM., Vol. 37, pp. 3953-3955 (1972)) in CH2CI2 (30 ml) was added Et3N (1. 57 ML, 11. 3 MMOL) and (t-BOC) 20 (1. 23 g, 5. 65 MMOL). After 3 h, the mixture was washed with sat. NH4CI (25 ml) and H20 (25 ML), dried over MGS04, filtered, and concentrated in vacuo to afford a yellow oil, which was purified via column chromatography with 50percent EtOAc/hexanes as eluant to give 0. 55 g of yellow oil in 38percent yield, which was used without any further purification. H NMR : 8 5. 12-4. 88 (1H, m), 3. 02 (3H, s), 1. 25 (9H, s).
Reference: [1] Patent: WO2004/74283, 2004, A1, . Location in patent: Page 39
[2] Patent: EP992493, 2000, A1,
  • 6
  • [ 67160-19-4 ]
  • [ 24424-99-5 ]
  • [ 141699-58-3 ]
Reference: [1] Synlett, 1998, # 4, p. 379 - 380
[2] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 5, p. 1517 - 1521
  • 7
  • [ 24424-99-5 ]
  • [ 141699-58-3 ]
Reference: [1] Patent: WO2011/160020, 2011, A2,
[2] Patent: WO2014/28800, 2014, A1,
[3] Journal of Medicinal Chemistry, 2014, vol. 57, # 18, p. 7731 - 7757
[4] Organic Process Research and Development, 2015, vol. 19, # 12, p. 2067 - 2074
[5] Patent: WO2017/12576, 2017, A1,
[6] Patent: WO2008/133734, 2008, A2,
  • 8
  • [ 773837-37-9 ]
  • [ 141699-58-3 ]
  • [ 142253-54-1 ]
Reference: [1] Patent: WO2010/131145, 2010, A1, . Location in patent: Page/Page column 85-86
[2] Patent: WO2016/206101, 2016, A1, . Location in patent: Page/Page column 89
  • 9
  • [ 143-33-9 ]
  • [ 141699-58-3 ]
  • [ 142253-54-1 ]
Reference: [1] Journal of Medicinal Chemistry, 2001, vol. 44, # 1, p. 94 - 104
  • 10
  • [ 141699-58-3 ]
  • [ 325775-44-8 ]
Reference: [1] Journal of Medicinal Chemistry, 2001, vol. 44, # 1, p. 94 - 104
  • 11
  • [ 2075-45-8 ]
  • [ 141699-58-3 ]
  • [ 877399-34-3 ]
YieldReaction ConditionsOperation in experiment
98% With sodium hydride In N,N-dimethyl-formamide at 110℃; for 0.5 h; Microwave irradiation A 5 mL microwave tube was charge with compound (2-4) (304 mg, 1.21 mmol); 4-bromopyrazole (2-5, 178 mg, 1.21 mmol) and NaH 60percent in mineral oil (73 mg, 1.82 mmol.) with 2 mL of DMF. The resulting mixture was microwaved at 110 C. for 30 minutes. The reaction mixture was partitioned between EtOAc (200 mL) and saturated NaHCO3 solution (2x50 mL); brine (50 mL). The organic layer was dried (Na2SO4), then concentrated by vacuum to afford 360 mg of (L) as yellow oil (98percent). 1H NMR (400 MHz, DMSO-D6) ? ppm 1.36-1.43 (m, 9H) 4.08 (s, 2H) 4.18-4.31 (m, 2H) 5.12-5.22 (m, 1H) 7.67 (s, 1H) 8.14 (s, 1H).
98% With sodium hydride In N,N-dimethyl-formamide at 110℃; for 0.5 h; Microwave irradiation A 5 mL microwave tube was charge with compound (2-4) (304 mg, 1.21 mmol); 4-bromopyrazole (2-5. 178 mg, 1.21 mmol) and NaH 60percent in mineral oil (73 mg, 1.82 mmol.) with 2 mL of DMF. The resulting mixture was microwaved at 110°C for 30 minutes. The reaction mixture was partitioned between EtOAc (200 mL) and saturated NaHCO3 solution (2 x 50 mL);brine (50 mL). The organic layer was dried (Na2SO4), then concentrated by vacuum to afford 360 mg of (2-6) as yellow oil (98percent). 1H NMR (400 MHz, DMSO-D6) 6 ppm 1.36 - 1.43 (m, 9 H) 4.08 (s, 2 H) 4.18 - 4.31 (m, 2 H) 5.12 - 5.22 (m, 1 H) 7.67 (s, 1 H) 8.14 (s, 1 H).
Reference: [1] Patent: US2006/46991, 2006, A1, . Location in patent: Page/Page column 57-58
[2] Patent: WO2006/21881, 2006, A2, . Location in patent: Page/Page column 62-63; 64
[3] Journal of Medicinal Chemistry, 2011, vol. 54, # 18, p. 6342 - 6363
  • 12
  • [ 269410-08-4 ]
  • [ 141699-58-3 ]
  • [ 877399-35-4 ]
Reference: [1] Patent: WO2008/148867, 2008, A2, . Location in patent: Page/Page column 59-60
[2] Patent: WO2009/106577, 2009, A1, . Location in patent: Page/Page column 117-118
[3] Journal of Medicinal Chemistry, 2011, vol. 54, # 18, p. 6342 - 6363
  • 13
  • [ 141699-58-3 ]
  • [ 877399-35-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 18, p. 6342 - 6363
  • 14
  • [ 141699-58-3 ]
  • [ 1064194-10-0 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 23, p. 6160 - 6163
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 141699-58-3 ]

Amides

Chemical Structure| 132945-75-6

[ 132945-75-6 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 141699-57-2

[ 141699-57-2 ]

tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 129888-60-4

[ 129888-60-4 ]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Chemical Structure| 404577-34-0

[ 404577-34-0 ]

(R)-1-N-Boc-3-Methanesulfonyloxypiperidine

Similarity: 0.87

Chemical Structure| 940890-90-4

[ 940890-90-4 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Sulfonates

Chemical Structure| 132945-75-6

[ 132945-75-6 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 141699-57-2

[ 141699-57-2 ]

tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 129888-60-4

[ 129888-60-4 ]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Chemical Structure| 404577-34-0

[ 404577-34-0 ]

(R)-1-N-Boc-3-Methanesulfonyloxypiperidine

Similarity: 0.87

Chemical Structure| 940890-90-4

[ 940890-90-4 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.87

Related Parent Nucleus of
[ 141699-58-3 ]

Azetidines

Chemical Structure| 141699-55-0

[ 141699-55-0 ]

tert-Butyl 3-hydroxyazetidine-1-carboxylate

Similarity: 0.68

Chemical Structure| 429669-07-8

[ 429669-07-8 ]

1-Boc-3-(methoxy)azetidine

Similarity: 0.67

Chemical Structure| 1104083-23-9

[ 1104083-23-9 ]

tert-Butyl 3-hydroxy-3-methylazetidine-1-carboxylate

Similarity: 0.67

Chemical Structure| 147621-21-4

[ 147621-21-4 ]

tert-Butyl azetidine-1-carboxylate

Similarity: 0.63

Chemical Structure| 325775-44-8

[ 325775-44-8 ]

tert-Butyl 3-(aminomethyl)azetidine-1-carboxylate

Similarity: 0.62